Skip to main content
PMC home page
Journal of Clinical Laboratory Analysis logoLink to Journal of Clinical Laboratory Analysis
. 2009 Sep 22;23(5):331–335. doi: 10.1002/jcla.20340

The utility of serum human epididymis protein 4 (HE4) in patients with a pelvic mass

Martina Montagnana 1,✉, Giuseppe Lippi 1, Orazio Ruzzenente 1, Valentina Bresciani 2, Elisa Danese 1, Silvia Scevarolli 2, Gian Luca Salvagno 1, Silvia Giudici 2, Massimo Franchi 2, Gian Cesare Guidi 1
PMCID: PMC6649112  PMID: 19774626

Abstract

Aim: Although CA125 is the most widely used cancer marker in the diagnostic approach of pelvic masses in women, its clinical usefulness is limited because it lacks expression of the antigen in the early stages of disease. The human epididymis protein 4 (HE4) is frequently over‐expressed in ovarian cancer, whereas its expression in normal tissues, including the ovary, is low. The aim of this study was to assess the concentration of both HE4 and CA125 in patients with different forms of benign and malign pelvic masses.

Methods: The study population included 99 patients with gynecological cancer (46 ovarian, 39 endometrial, 14 cervical) and 40 affected by benign disease (22 endometriosis and 18 benign ovarian mass). Twelve control subjects were also included in the study. In all the patients, serumsamples were collected on the day before scheduled surgery.

Results: The median CA125 and HE4 serum levels were significantly higher among ovarian cancer patients as compared with healthy subjects and with those with benign mass, cervical, and endometrial tumors. The receiver operating characteristics curve analysis on healthy controls and patients with ovarian cancers revealed that HE4 had a significantly higher area under the curve when compared with CA125 (0.99 vs. 0.91), with a sensibility and specificity of 98 and 100%, respectively.

Conclusions: HE4 seems to be a promising ovarian cancer marker, and its measurement might improve the diagnostic approach to patients with pelvic masses. J. Clin. Lab. Anal. 23:331–335, 2009. © 2009 Wiley‐Liss, Inc.

Keywords: HE4, CA125, pelvic mass, ovarian cancer, cancer markers

REFERENCES

  • 1. Colombo N, Van Gorp T, Parma G, et al. Ovarian cancer. Crit Rev Oncol Hematol 2006;60:159–179. [DOI] [PubMed] [Google Scholar]
  • 2. Pal T, Permuth‐Wey J, Sellers TA. A review of the clinical relevance of mismatch‐repair deficiency in ovarian cancer. Cancer 2008;113:733–742. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3. Heitz APM, Odicino F, Maisonneuve P, et al. Carcinoma of the ovary. Int J Gynecol Obstet 2006;95:S161–S192. [DOI] [PubMed] [Google Scholar]
  • 4. Dunleavey R. Importance of early diagnosis in managing ovarian cancer. Nurs Times 2006;102:28–29. [PubMed] [Google Scholar]
  • 5. Evans J, Ziebland S, McPherson A. Minimizing delays in ovarian cancer diagnosis: An expansion of Andersen's model of “total patient delay”. Fam Pract 2007;24:48–55. [DOI] [PubMed] [Google Scholar]
  • 6. Schwartz DR, Wu R, Kardia SL, et al. Novel candidate targets of beta‐catenin/T‐cell factor signaling identified by gene expression profiling of ovarian endometrioid adenocarcinomas. Cancer Res 2003;63:2913–2922. [PubMed] [Google Scholar]
  • 7. Grisaru D, Hauspy J, Prasad M, et al. Microarray expression identification of differentially expressed genes in serous epithelial ovarian cancer compared with bulk normal ovarian tissue and ovarian surface scrapings. Oncol Rep 2007;18:1347–1356. [PubMed] [Google Scholar]
  • 8. Berry NB, Cho YM, Harrington MA, Williams SD, Foley J, Nephew KP. Transcriptional targeting in ovarian cancer cells using the human epididymis protein 4 promoter. Gynecol Oncol 2004;92:896–904. [DOI] [PubMed] [Google Scholar]
  • 9. Drapkin R, von Horsten HH, Lin Y, et al. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res 2005;65:2162–2169. [DOI] [PubMed] [Google Scholar]
  • 10. Hellström I, Raycraft J, Hayden‐Ledbetter M, et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res 2003;63:3695–3700. [PubMed] [Google Scholar]
  • 11. Havrilesky LJ, Whitehead CM, Rubatt JM, et al. Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence. Gynecol Oncol 2008;110:374–382. [DOI] [PubMed] [Google Scholar]
  • 12. Galgano MT, Hampton GM, Frierson HF Jr. Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod Pathol 2006;19:847–853. [DOI] [PubMed] [Google Scholar]
  • 13. Heintz AP, Odicino F, Maisonneuve P, et al. Carcinoma of the ovary. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 2006;95:S161–S192. [DOI] [PubMed] [Google Scholar]
  • 14. Shepherd JH. Revised FIGO staging for gynaecological cancer. Br J Obstet Gynaecol 1989;96:889–892. [DOI] [PubMed] [Google Scholar]
  • 15. Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E, Vergote I. Endometrial cancer. Lancet 2005;366:491–505. [DOI] [PubMed] [Google Scholar]
  • 16. Bast RC Jr, Feeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 1981;68:1331–1337. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17. Rustin GJ, Bast RC Jr, Kelloff GJ, et al. Use of CA‐125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer. Clin Cancer Res 2004;10:3919–3926. [DOI] [PubMed] [Google Scholar]
  • 18. Jacobs I, Oram D, Fairbanks J, Turner J, Frost C, Grudzinskas JG. A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. Br J Obstet Gynaecol 1990;97:922–929. [DOI] [PubMed] [Google Scholar]
  • 19. Bast RC Jr, Brewer M, Zou C, et al. Prevention and early detection of ovarian cancer: Mission impossible? Recent Results Cancer Res 2007;174:91–100. [DOI] [PubMed] [Google Scholar]
  • 20. Rosen DG, Wang L, Atkinson JN, et al. Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol 2005;99:267–277. [DOI] [PubMed] [Google Scholar]
  • 21. Moore RG, Brown AK, Miller MG, et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol 2008;108:402–408. [DOI] [PubMed] [Google Scholar]
  • 22. Ayhan A, Guven S, Guven ES, Kucukali T. Is there a correlation between tumor marker panel and tumor size and histopathology in well staged patients with borderline ovarian tumors? Acta Obstet Gynecol Scand 2007;86:484–490. [DOI] [PubMed] [Google Scholar]
  • 23. Yin BW, Lloyd KO. Molecular cloning of the CA125 ovarian cancer antigen: Identification as a new mucin, MUC16. J Biol Chem 2001;276:27371–27375. [DOI] [PubMed] [Google Scholar]
  • 24. Ligtenberg MJ, Kruijshaar L, Buijs F, van Meijer M, Litvinov SV, Hilkens J. J Biol Chem 1992;267:6171–6177. [PubMed] [Google Scholar]
  • 25. Boshell M, Lalani E‐N, Pemberton L, Burchell J, Gendler S, Taylor‐Papadimitriou J. The product of the human MUC1 gene when secreted by mouse cells transfected with the full length. cDNA lacks the cytoplasmic tail. Biochem Biophys Res Commun 1992;185:1–8. [DOI] [PubMed] [Google Scholar]
  • 26. Moore RG, Brown AK, Miller MG, et al. Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus. Gynecol Oncol 2008;110:196–201. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Laboratory Analysis are provided here courtesy of Wiley

RESOURCES